<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071161</url>
  </required_header>
  <id_info>
    <org_study_id>NL19886.075.08</org_study_id>
    <nct_id>NCT01071161</nct_id>
  </id_info>
  <brief_title>The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough</brief_title>
  <acronym>CACTUS</acronym>
  <official_title>Phase III (c) The Effect of Azithromycin in Patients With COPD and Chronic Productive Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isala</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of azithromycin to produce a&#xD;
      significant change in the cough-related health status, measured with the Dutch version of the&#xD;
      Leicester Cough Questionnaire in patiÃ«nts with COPD gold classification 2-4 and chronic&#xD;
      productive coughing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective double-centre, double blind randomised trial. Patients &gt; 40 years&#xD;
      of age, referred to our outpatient clinic with chronic cough and sputum production due to&#xD;
      COPD will be recruited after informed consent is obtained.&#xD;
&#xD;
      Consenting patients will be randomises to a 12-week treatment with 250 mg azithromycin three&#xD;
      times a week or placebo.&#xD;
&#xD;
      Before randomisation all patients have to fill in the SF 36 , SGRQ and the Dutch version of&#xD;
      the Leicester Cough Questionnaire (LCQ) for assessment of the baseline quality of life and&#xD;
      the disease specific quality of life.&#xD;
&#xD;
      The LCQ questionnaires will be performed at the beginning and every 3 weeks afterwards until&#xD;
      18 weeks, except the second LCQ which will be filled in after 2 weeks. Scores from this&#xD;
      questionnaire will be used to calculate the 2-week repeatability. The SF 36 and SGRQ will be&#xD;
      performed at the start of the study and after 12 weeks. Adverse events will be recorded&#xD;
      during the whole treatment period. After 2 and 12 weeks a Global Rating of Change will be&#xD;
      performed. This questionnaire will be used to validate the LCQ in COPD patients.&#xD;
&#xD;
      Randomisation will take place using a computer allocation program (BAMI-computer)&#xD;
&#xD;
      Azithromycin and placebo will be provided by Teva Pharmaceuticals. Placebo and azithromycin&#xD;
      will be identical in appearance and packaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the Leicester Cough Questionnaire (LCQ) scores.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the SF 36 and SGRQ scores.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lung function, (FEV1 (L) and FVC (L)).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exacerbations.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory values: CRP, ASAT, ALAT</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum analysis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Cough</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>azithromycin, tablets, during 12 weeks, three times a week, 250mg</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 40 years of age, in our outpatient clinic with chronic cough and COPD&#xD;
             (gold2-4)&#xD;
&#xD;
          -  Chronic cough is defined as a cough &gt; 12 weeks duration, at least 12 weeks a year in 2&#xD;
             subsequent years.&#xD;
&#xD;
          -  Analysed for bronchiectasis prior to participation by CT-thorax.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of asthma&#xD;
&#xD;
          -  Use of i.v. or oral corticosteroids and or antibiotics for an exacerbation 3 weeks&#xD;
             before inclusion&#xD;
&#xD;
          -  Patients suffering from other relevant lung diseases.&#xD;
&#xD;
          -  Clinically relevant abnormal laboratory values suggesting an unknown disease requiring&#xD;
             further clinical evaluation.&#xD;
&#xD;
          -  Liver disease, (ALAT and/or ASAT levels two or more times the upper limit of normal).&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Use of macrolides the last 6 weeks prior to inclusion.&#xD;
&#xD;
          -  Allergy or intolerance to macrolides.&#xD;
&#xD;
          -  Other research medication started 2 months prior to inclusion.&#xD;
&#xD;
          -  Prior randomisation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan W van den Berg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pulmonology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Ov</state>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isala</investigator_affiliation>
    <investigator_full_name>Jan W.K. van den Berg</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>chronic cough</keyword>
  <keyword>COPD</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Zithromax</keyword>
  <keyword>LCQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

